CANNABIDIOL


(CBD) AND EMPLOYMENT DRUG TESTING


What Employers and Employees Need to Know


A


BY NICK HARTMAN (C-DER), FOUNDER, DRUG SCREENING COMPLIANCE INSTITUTE (DSCI)


18 datia focus


t the Drug Screening Compliance Institute, we get asked questions about workplace drug & alcohol


screening programs every day. As of recently, by far the topic we hear most is around the increase of popularity with Cannabidiol (CBD) use and how it may impact workplace substance abuse screening programs. Te question posed is one of great interest to employers & its product users, especially with the waves of recent press and how quickly CBD products are gaining national atention and record-seting sales figures1


. Te


numbers don't lie. Hemp and CBD product sales reached $821 million in 2017 and are expected to skyrocket to $1.9 billion by 2022.


summer 2019


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40